Cargando…
Serum levels of cytokines in infants treated with conbercept for retinopathy of prematurity
Intravitreal anti-vascular endothelial growth factor (VEGF) agents have revolutionized the treatment of retinopathy of prematurity (ROP); however, there are concerns regarding the potential systemic complications caused by those treatments. This study aimed to determine the serum concentrations of c...
Autores principales: | Cheng, Yong, Zhu, Xuemei, Linghu, Dandan, Xu, Yongsheng, Liang, Jianhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391743/ https://www.ncbi.nlm.nih.gov/pubmed/32728160 http://dx.doi.org/10.1038/s41598-020-69684-7 |
Ejemplares similares
-
A lower dose of intravitreal conbercept effectively treats retinopathy of prematurity
por: Cheng, Yong, et al.
Publicado: (2018) -
Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China
por: Linghu, Dandan, et al.
Publicado: (2022) -
Intraocular pressure effect of intravitreal conbercept injection for retinopathy of prematurity
por: Gao, Caifeng, et al.
Publicado: (2023) -
Fluorescein Angiographic Findings of Peripheral Retinal Vasculature after Intravitreal Conbercept versus Ranibizumab for Retinopathy of Prematurity
por: Jin, Enzhong, et al.
Publicado: (2019) -
Analysis of non-retinopathy of prematurity (ROP)–related fundus hemorrhage in preterm infants in China
por: Yaoyao, Sun, et al.
Publicado: (2022)